SecBot SecBot

Creating Hope Reauthorization Act of 2024

H.R. 7384 Rep. Michael McCaul (R-TX-10) In committee
Bill text PDF
  1. Introduced Feb 15
  2. Committee Feb 15
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 15, 2024Next: House vote
985d ago Feb 16, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
11companies, 18 filings
Subscribe to see spend
Member trades
8trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

11 companies
Companies by sector
Biotech & Pharma 11
Search all 11 companies, their asks and price moves Subscribe

Summary

Creating Hope Reauthorization Act of 2024

Full summary1 paragraphs

This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)

Library of Congress summary, Feb 15, 2024

Summary versions
  • Introduced in HouseFeb 15, 2024

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.